AzTrials
AzTrials

Restless Leg SyndromeNCT07110961

The Suggested Immobilization Test With Exploratory Heart Rate Variability Analysis for Diagnosis of Restless Legs Syndrome

A study testing A suggested immobilization test (SIT) in people with Restless Leg Syndrome, run by Siriraj Hospital at 1 site in Thailand.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Restless leg syndrome (RLS) is not uncommon and can also affect people's health and quality of life. Mainly, RLS is diagnosed based on clinical criteria subjectively. Sometimes it is difficult to differentiate between RLS and mimickers, especially in patients with comorbidities such as diabetes or parkinson's disease. Read more about this study

Who is it for?
Ages 18 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Restless Leg Syndrome
What is being tested?
A suggested immobilization test (SIT)
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
52 participants
Where
1 siteThailand
Study dates
1 Oct 2025to 31 Dec 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Patients who were appointed for an in-lab polysomnographic study and fit the clinical diagnosis criteria for restless leg syndrome based on International Restless Legs Syndrome Study Group (IRLSSG)

Who cannot join

  • Patient with physical limitations including stroke, dementia or hearing impairment
  • Pregnant women

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Jindapa Srikajon, M.D. contact

+66875932929

jindapa.sri@mahidol.ac.th

Thailand1 site, 1 recruiting
  • Faculty of Medicine, Siriraj Hospital, Mahidol University

    Bangkok, Bangkok, 10700

    Pakjira Na Nan, +624197536, pakjira.nan@mahidol.ac.th

    Recruiting

Other trials in Thailand

About this study

Official title: Diagnostic Accuracy of the Suggested Immobilization Test With Exploratory Heart Rate Variability Analysis for Restless Legs Syndrome in a Thai Population

Restless leg syndrome (RLS) is not uncommon and can also affect people's health and quality of life. Mainly, RLS is diagnosed based on clinical criteria subjectively. Sometimes it is difficult to differentiate between RLS and mimickers, especially in patients with comorbidities such as diabetes or parkinson's disease. We believe that using objective tests would facilitate accuracy in RLS diagnosis, which leads to proper management of patients.

Read the detailed description

Restless legs syndrome (RLS) represents disturbing symptoms in the lower limbs that lead to the urge to move, occurring in rest periods. Movements can partially or completely relieve these abnormal feelings. In 2014, the International RLS Study Group (IRLSSG) established five mandatory criteria for the diagnosis of RLS1.

IRLSSG essential diagnostic criteria for RLS (all must be met):

  • An urge to move the legs, usually but not always accompanied by, or felt to be caused by, uncomfortable and unpleasant sensations in the legs
  • The urge to move the legs and any accompanying unpleasant sensations begin or worsen during periods of rest or inactivity, such as lying down or sitting
  • The urge to move the legs and any accompanying unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues
  • The urge to move the legs and any accompanying unpleasant sensations during rest or inactivity only occur or are worse in the evening or night than during the day.
  • The occurrence of the above features is not solely accounted for as symptoms primary to another medical or a behavioral condition (e.g., myalgia, venous stasis, leg edema, arthritis, leg cramps, positional discomfort, habitual foot tapping) In the general population, a prevalence of RLS was reported up to 10%2. The prevalence of RLS varies considerably depending on the methods of diagnosis, country, sex, age, and comorbidity burden, which impedes comparisons between studies3. Generally, the prevalence of RLS is relatively low, approximately 1% in Asian populations4-6. In contrast, the prevalence of RLS is considerably higher, ranging from 5% to 10% in Europe and North America7. A cross-sectional nationwide survey of 6,509 Korean adults aged 18-64, using criteria established by the International RLS Study Group (IRLSSG) to define RLS, found a prevalence of 0.9% (0.6% in men and 1.3% in women)5. There was only one study focusing on the prevalence of RLS in Thailand, in which the prevalence of RLS in Thai Parkinson's patients was only 1.6%8.

The nonpharmacologic treatment of RLS includes stretching, heating, or cooling the extremities (e.g., a warm bath), and avoiding alcohol and caffeine. However, the U.S. Food and Drug Administration (FDA) has not approved physical devices such as compression stockings, heating and vibrating pads, and foot pressure wraps for the treatment of RLS9.

Pharmacologic treatment: The latest clinical practice guideline (CPG) updates the 2024 American Academy of Sleep Medicine (AASM) practice parameters and offers new recommendations for treating RLS in adult patients. The primary change in these recommendations is the inclusion of alpha-2-delta ligands (gabapentin, gabapentin enacarbil, and pregabalin) in the 'strong recommendation' category, along with a transition from the use of dopamine agonists to a 'conditional recommendation' in order to mitigate side effects such as augmentation and impulse control disorders 10.

Patients with RLS experience significant adverse effects on work performance, quality of life, cognition, and health11,12. A survey study conducted in the United States that examined the disease burden of primary RLS found that work productivity is diminished by approximately 20%, which equates to about one day per 40-hour work week for individuals with moderate to severe RLS. The mean EQ-5D health utility score indicated a significantly lower health status compared to the healthy control group. Additionally, RLS negatively impacts sleep quality, with 60-70% of patients reporting poor sleep11. RLS not only causes impaired quality of life but also possibly leads to cardiovascular consequences. RLS was associated with statistically significantly less future cardiovascular risk in RLS patients with treatment than in those without treatment13.

The diagnosis of RLS is primarily based on a clinical history of an urge to move the limbs that worsens when at rest, improves with movement, and is more prominent in the evening or at night. These four criteria have a positive predictive value (PPV) of 76% when an expert interview is used as the gold standard. Carefully distinguishing RLS from leg cramps or positional discomfort increases the specificity of the four criteria from 84% to 94%14. However, some RLS mimics, such as nocturnal leg cramps or neuropathy, still cannot be addressed solely by clinical history or basic RLS screening instruments. Consequently, there should be standardized objective tests for RLS beyond clinical diagnosis.

The Suggested Immobilization Test (SIT) is a provocative test. RLS symptoms (urge to move the leg and leg paresthesia) are primarily observed during wakefulness, especially at rest, in the evening, and/or during the night. During the test, the patient remains in a bed (or a reclining chair), at a 45° angle with legs outstretched. Originally, the SIT only quantified leg motor activity. Since 2002, it also includes the assessment of leg discomfort, which is estimated by the patient every 5 min, on a 100-mm horizontal visual analogue scale. Leg movements are quantified using surface electromyography (EMG) from bilateral anterior tibialis muscles. Using these pathological thresholds, the clinical RLS/WED diagnosis is correctly predicted in 88% of subjects with a sensitivity of 82% and a specificity of 100%15,16.

It was not only used for diagnosis but also for measuring the severity of symptoms. Patients with severe RLS show more leg movements during the SIT than those with moderate or mild RLS. Additionally, it can help differentiate RLS mimics, which can be challenging with only a clinical diagnosis, as mentioned above. Moreover, it would benefit special populations, especially those with Parkinson's disease or Multiple sclerosis, who have some symptoms that could confound the diagnosis of restless leg syndrome17,18. The low cost and the ability to repeat the tests multiple times throughout the day are the two main advantages of SIT. It can also be done on the same day as a routine sleep test.

To the best of investigator's knowledge, this is the first pilot study of SIT for confirmation of restless leg syndrome in the Thai population. Early diagnosis with a high-accuracy test would lead to appropriate treatment planning and better outcomes in Thai RLS patients.

Being tested
A suggested immobilization test (SIT)
Keywords
restless leg syndrome, sleep, suggested immobilization test
Medical subject headings
Restless Legs Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • A suggested immobilization test (SIT)Procedure or surgery

    The Suggested Immobilization Test (SIT) is a provocative test. RLS symptoms (urge to move the leg and leg paresthesia) are primarily observed during wakefulness, especially at rest, in the evening, and/or during the night. During the test, the patient remains in a bed (or a reclining chair), at a 45° angle with legs outstretched. Originally, the SIT only quantified leg motor activity. Since 2002, it also includes the assessment of leg discomfort, which is estimated by the patient every 5 min, on a 100-mm horizontal visual analogue scale. Leg movements are quantified using surface electromyography (EMG) from bilateral anterior tibialis muscles. Using these pathological thresholds, the clinical RLS/WED diagnosis is correctly predicted in 88% of subjects with a sensitivity of 82% and a specificity of 100%. Heart rate variability was recorded though ECG II channel.

Study groups in NCT07110961
Study groupRoleWhat they receive
Clinical diagnosed restless leg syndromeExperimentalParticipants with appointment of sleep test and clinical diagnosed restless leg syndrome according to International Restless Legs Syndrome Study Group (IRLSSG) are reruited and undergo a suggested immobilization test before the standard polysomnographic study.
Receives: Procedure: A suggested immobilization test (SIT)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Correlation between clinical diagnosis based on criteria and results from a suggested immobilization test

    Between-group and correlation analyses between categorical and continuous data were corrected using Spearman's rank correlation.

    Measured: During intervention

Secondary outcomes (2)
  1. Occurence of advense events from a suggested immobilization test

    discomfort or any unconfotable feeling during the test will be recorded.

    Measured: During intervention

  2. Heart rate variability changes during SIT

    Heart Rate Variability Assessment Electrocardiographic signals were recorded continuously during a baseline resting period preceding the SIT and throughout the test. HRV analysis was performed using validated software following artifact correction and manual inspection of R-R intervals.

    Time-domain parameters included the root mean square of successive differences (RMSSD) and the standard deviation of normal-to-normal intervals (SDNN).

    Frequency-domain parameters included low-frequency (LF) power, high-frequency (HF) power, and the LF/HF ratio.

    HRV parameters during early (first 5 minutes) and the late SIT period (last 5 minutes) were compared between participants with and without RLS. HRV analysis was predefined as an exploratory secondary outcome.

    Measured: During the SIT prior to sleep test

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Aug 2025
  2. Study start1 Oct 2025
  3. Primary completion30 Sep 2026 (estimated)
  4. Study completion31 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Model description
All participants will undergo a suggested immobilization test on the same day of the sleep test appointment.
Masking
None (open label)
Enrolment
52 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07110961
Sponsor's protocol ID
645/2568(IRB4)
Status last verified
Feb 2026
First submitted
25 Jul 2025
Last updated
13 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Still deciding

Questions about this trial

What is this clinical trial studying?

A study testing A suggested immobilization test (SIT) in people with Restless Leg Syndrome, run by Siriraj Hospital at 1 site in Thailand.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jindapa Srikajon, M.D. (+66875932929, jindapa.sri@mahidol.ac.th), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Correlation between clinical diagnosis based on criteria and results from a suggested immobilization test (time frame: During intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in